enGene Q3 net loss $28.9M; hits LEGEND enrollment target, RMAT designation

enGene Therapeutics Inc.

2025-Q3 EPS reported $1.56

Cash and marketable securities $224.9M; net loss $28.9M ($0.57/share) vs $14.1M ($0.32/share) YoY.
Achieved target enrollment of 100 patients in LEGEND pivotal cohort; data update expected 4Q 2025.
Detalimogene granted FDA RMAT designation; BLA submission planned for 2H 2026.
Operating expenses $29.9M, up from $16.8M; R&D costs increased $11M on LEGEND manufacturing and clinical costs.
Board appointed Philip Astley-Sparke, William Grossman, Michael Heffernan; promoted Matthew Boyd, Jill Buck, Katherine Chan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.